Maria Eleftheria A. Evangelopoulos, Greece

Eginition University Hospital- National and Kapodistrian University of Athens Neurology Department, Demyalinating Diseases Unit
Maria Eleftheria Evangelopoulos is an Assistant Professor of Neurology and Neurochemistry at the Medical School, National and Kapodistrian University of Athens, Greece. She works at the Demyelinating Diseases Unit, at the 1st Department of Neurology, Eginition University Hospital. She graduated for the Medical School of the National and Kapodistrian University of Athens. She did her Doctoral Thesis in Immunology at the National and Kapodistrian University of Athens, studying the immune indices in clinical and subclinical autoimmune disorders. She continued with her PhD in Neuroscience in the University of Bern, Switzerland where she studied the mechanisms of neuronal differentiation, the action of neurotrophins and their receptors as well as the molecular signaling involved. She completed her residency training in neurology in Inselspital Bern and at the 1st Department of Neurology, National and Kapodistrian University of Athens, Greece. She was then further subspecialized at the Neurology Department of Inselspital Bern as a fellow of European Neurological Society. Her clinical, educational and research activities focus on clinical neurology, neurochemistry, neuroimmunology and immunology. She has a special interest on Demyelinating Diseases as multiple sclerosis and neuromyelitis optica. She has published a large number of articles in peer-reviewed journals as well as abstracts in international and Greek conferences in the field of clinical neurology, neurochemistry and neuroimmunology. As an invited speaker she has participated in many National and International congresses and has also served as invited reviewer in National and International Journals.

Presenter of 1 Presentation

INVESTIGATION OF GLUCOCORTICOID SENSITIVITY IN MULTIPLE SCLEROSIS PATIENTS IN RELAPSE

Session Type
PARALLEL SESSIONS
Date
31.05.2021, Monday
Session Time
13:30 - 15:30
Room
HALL B
Lecture Time
14:10 - 14:20
Session Icon
Pre Recorded

Abstract

Background and Aims

Glucocorticoids (GCs) are used for the treatment of relapse multiple sclerosis.(MS). Decreased sensitivity to GCs in MS patients has been associated with lack of suppressive effect of GCs on inflammatory molecules, increased resistance to apoptosis which in turn affect the response to high intravenous methylprednisolone (IVMP). We investigated GC-sensitivity by measuring the effect of IVMP treatment on transactivation of anti-inflammatory, anti-apoptotic and apoptotic genes (GILZ, MCL-1 and NOXA respectively) in accordance to clinical outcome.

Methods

We studied 24 MS patients: clinically isolated syndrome (CIS/n=9), relapsing remitting (RRMS/n=8) and secondary progressive (SPMS/n=7) under relaspe. Patients underwent treatment with IVMP (1000mg/day) for 5 consecutive days. Blood was drawn on before and 1 hour after IVMP on day 1 and also 1h after 5th IVMp. GIlZ, MCL-1 and NOXA gene expression was determined by qPCR. The Expanded Disability Status was also evaluated before and after IVMP (on 5th day) and all patients were divided according to their clinical response into two groups.

Results

Our data demonstrate that the GILZ and MCL-1 gene expression were significantly higher after first IVMP injection (day1) in clinical responders compared to non-clinical responders (p≤0.05). However, the NOXA gene expression 1h after 5th IVMP was significantly higher in clinical responders as compared to non-clinical responders (p≤0.05).

Conclusions

Our findings suggest that the differential GILZ and MCL-1 gene expression between clinical responders and non-clinical responders implicate the importance of GILZ and MCL-1 as possible markers for predicting glucocorticoid sensitivity and response to GC-therapy in MS patients after the first IVMP treatment.

Hide